Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
76 hedge funds and large institutions have $135M invested in Novelion Therapeutics Inc. Common Shares in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 11 closing their positions.
2,756% more call options, than puts
Call options by funds: $257K | Put options by funds: $9K
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
15% more funds holding
Funds holding: 66 → 76 (+10)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
7% less capital invested
Capital invested by funds: $146M → $135M (-$10.3M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.31M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$5.12M |
| 3 |
Morgan Stanley
New York
|
+$4.45M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.81M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingstown Capital Management
New York
|
-$6.44M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.98M |
| 3 |
Millennium Management
New York
|
-$1.25M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$893K |
| 5 |
Two Sigma Investments
New York
|
-$709K |
NVLN Hedge Fund Activity: Q2 2017 in Review
76 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q2 2017, worth a combined $135M — down 7% from $146M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NVLN positions and 11 closed out — a net gain of 10 holders — while 17 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $6.31M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $6.44M sold.
- 76 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q2 2017, up from 66 in Q1 2017.
- Funds reported $135M of Novelion Therapeutics Inc. Common Shares stock for Q2 2017, down 7% quarter-over-quarter.
- 21 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q2 2017 and 11 closed out, a net change of +10 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q2 2017 was BlackRock, an estimated $6.31M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q2 2017 was Kingstown Capital Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q2 2017.